Metformin for Hidradenitis Suppurativa

• Conditions: Hidradenitis Suppurativa

• Registration Number: NL-OMON25659
• Lead Sponsor: ZonMw

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 62

Inclusion Criteria

•Age =18 years at baseline
•A diagnosis of HS for at least 1 year prior to baseline
•mild to moderately active disease defined by a HS Physician Global Assessment (HS-PGA) score of 2-3 and the Refined Hurley classification of mild to moderate at baseline
•Indication for systemic therapy; i.e. uncontrolled disease under conventional topical therapy.
•Able and willing to give written informed consent and to comply with the study requirements

Exclusion Criteria

•Pregnant and lactating women
•Concomitant diabetes mellitus
•Use of antibiotics within 14 days prior to baseline
•Use of immunosuppressing/modulating therapies within 28 days prior to baseline
•A known allergy to metformin or doxycycline or any of the ingredients metformin or doxycycline

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
International Hidradenitis Suppurativa Severity Score System (IHS4)

Secondary Outcome Measures

Name	Time	Method
Insulin resistance and metabolic syndrome<br>Clinical efficacy<br>patient reported outcomes as NRS-pain, DLQI, Flares, treatment satisfaction and recommendation<br>Cost-effectiveness <br>Bio-markers<br>Safety and Tolerability